The FDA Cellular, Tissue, and Gene Therapies Advisory Committee meets at 9:30 a.m. ET on July 30 to discuss and make recommendations on Biologics License Application 125842 from Capricor Inc. for Deramiocel (human allogeneic cardiosphere-derived cells) in the treatment of cardiomyopathy in Duchenne muscular dystrophy.
REPLAY: FDA Cellular, Tissue, and Gene Therapies Advisory Committee Meets on Biologics License for Deramiocel (Day 2)
REPLAY: FDA Cellular, Tissue, and Gene Therapies Advisory Committee Meets on Biologics License for Deramiocel (Day 2)
Jul-30-2026